PARP Inhibitors in Reproductive System Cancers: Current Use and Developments.
about
Targeting the ATR-CHK1 Axis in Cancer TherapyNiraparib: First Global Approval.Candidate synthetic lethality partners to PARP inhibitors in the treatment of ovarian clear cell cancer.Current status of poly(ADP-ribose) polymerase inhibitors and future directions.Editorial: US Cancer Statistics of Survival: Achievements, Challenges, and Future Directions.PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers.
P2860
PARP Inhibitors in Reproductive System Cancers: Current Use and Developments.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 January 2017
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
PARP Inhibitors in Reproductive System Cancers: Current Use and Developments.
@en
PARP Inhibitors in Reproductive System Cancers: Current Use and Developments.
@nl
type
label
PARP Inhibitors in Reproductive System Cancers: Current Use and Developments.
@en
PARP Inhibitors in Reproductive System Cancers: Current Use and Developments.
@nl
prefLabel
PARP Inhibitors in Reproductive System Cancers: Current Use and Developments.
@en
PARP Inhibitors in Reproductive System Cancers: Current Use and Developments.
@nl
P2093
P2860
P921
P1433
P1476
PARP Inhibitors in Reproductive System Cancers: Current Use and Developments.
@en
P2093
Alice P Chen
James H Doroshow
Robert Meehan
P2860
P2888
P304
P356
10.1007/S40265-016-0688-7
P5008
P577
2017-01-11T00:00:00Z
2017-02-01T00:00:00Z